Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Omeros Corp (NQ: OMER )

4.010 +0.240 (+6.37%)
Streaming Delayed Price Updated: 12:13 PM EDT, Jun 13, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Omeros Corp

< Previous 1 2 3 4 5 6 7 8 Next >
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Gainers Omeros (NASDAQ:OMER) stock increased by 15.68% to $7.89 during Thursday's pre-market session. The market value of their outstanding shares is at $493.4 million... 
Via Benzinga
Omeros Announces Agreement to Sell OMIDRIA® Franchise to Rayner Surgical in a Transaction Valued in Excess of $1 Billion
From Omeros Corporation
Via Business Wire
Omeros: Q3 Earnings Insights
Omeros (NASDAQ:OMER) reported its Q3 earnings results on Tuesday, November 9, 2021 at 04:00 PM. Here's what investors need to know about the announcement. Earnings Omeros... 
Via Benzinga
Omeros Corporation Reports Third Quarter 2021 Financial Results
From Omeros Corporation
Via Business Wire
76 Biggest Movers From Yesterday
Gainers Expensify, Inc. (NASDAQ: EXFY) jumped 52.1% to settle at $41.06 on Wednesday after the company priced its IPO at $27 per share. RenovoRx, Inc. (NASDAQ: RNXT) shares... 
Via Benzinga
Topics Initial Public Offering
Exposures Securities Market
Earnings Outlook For Omeros
Omeros (NASDAQ:OMER) is set to give its latest quarterly earnings report on Tuesday, 2021-11-09. Here's what investors need to know before the announcement. Analysts estimate that... 
Via Benzinga
The Daily Biotech Pulse: Double Dose Of Positive Tidings For Merck, Alkermes Slips On Partial Termination Of J&J Licensing Deal, Amgen Migraine Drug Data
Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Merck Gets Antitrust Nod For Acceleron Deal In Germany, Austria, Announces... 
Via Benzinga
Omeros' Narsoplimab Shows Improved, Stabilized Renal Function At Three Years
Omeros Corporation (NASDAQ: OMER) announced long-term follow-up (35 months) results from the Phase 2 trial of its MASP-2 inhibitor narsoplimab in patients with IgA... 
Via Benzinga
Omeros Announces Results From Nearly Three-Year Follow-up of Patients in Phase 2 IgA Nephropathy Trial
From Omeros Corporation
Via Business Wire
Omeros’ Narsoplimab Stabilized Kidney Function and Reduced Urinary Complement Proteins in a Patient with IgA Vasculitis
From Omeros Corporation
Via Business Wire
Omeros Corporation to Announce Third Quarter Financial Results on November 9, 2021
From Omeros Corporation
Via Business Wire
Attention Biotech Investors: Mark Your Calendar For November PDUFA Dates
The loaded Prescription Drug User Fee Act (PDUFA) calendar for October produced mixed outcomes. PDUFA dates are key binary events for biotech stocks that can move the needle in a... 
Via Benzinga
3 Beaten-Down Biotech Stocks -- Can They Recover?
Each for reasons of their own, Atea Pharmaceuticals, Omeros, and Novavax have had a very tough time this year. 
Via The Motley Fool
NASDAQ:OMER Investor Notice: Investigation over Possible Securities Laws Violations by Omeros Corporation
San Diego, CA -- (SBWIRE) -- 10/22/2021 -- An investigation was announced concerning potential securities laws violations by Omeros Corporation in connection with certain financial statements. 
Via SBWire
10 Biggest Price Target Changes For Tuesday
Goldman Sachs boosted Walmart Inc. (NYSE:WMT) price... 
Via Benzinga
46 Biggest Movers From Yesterday
Gainers Valneva SE (NASDAQ: VALN) shares surged 39.8% to close at $39.21 on Monday after the company reported VLA2001 met both co-primary endpoints in the Phase 3 pivotal trial... 
Via Benzinga
Omeros Stock Falls As FDA Asks For More Clinical Narsoplimab Data In HSCT-TMA
The FDA issued a Complete Response Letter (CRL) related to Omeros Corporation's (NASDAQ: OMER) marketing application for narsoplimab for hematopoietic... 
Via Benzinga
Exposures Product Safety
Mid-Afternoon Market Update: Dow Falls 70 Points; Evolving Systems Shares Spike Higher
Toward the end of trading Monday, the Dow traded down 0.20% to 35,223.86 while the NASDAQ rose 0.68% to 14,998.54. The S&P also rose, gaining 0.19% to 4,480.05. The U.S. has... 
Via Benzinga
Topics Stocks
Exposures US Equities
Benchmarks Pare Losses on Upbeat Earnings Outlook
The major benchmarks are paring earlier losses at midday, fresh off of their best week in months as earnings season kicks off. 
Via Talk Markets
12 Health Care Stocks Moving In Monday's Intraday Session
Gainers Progenity (NASDAQ:PROG) shares increased by 33.17% to $2.85 during Monday's regular session. As of 12:30 EST, Progenity's stock is trading at a volume of... 
Via Benzinga
Mid-Day Market Update: Nasdaq Rises 50 Points; Revance Therapeutics Shares Plummet
Midway through trading Monday, the Dow traded down 0.05% to 35,275.96 while the NASDAQ rose 0.34% to 14,948.46. The S&P also rose, gaining 0.19% to 4,479.71. The U.S. has the... 
Via Benzinga
Topics Stocks
Exposures US Equities
Here's Why Omeros Is Sinking Further Today
Bad news the company received today from the FDA surprised investors more than it probably should have. 
Via The Motley Fool
Exposures Product Safety
34 Stocks Moving In Monday's Mid-Day Session
Gainers Valneva SE (NASDAQ: VALN) shares jumped 34.6% to $37.75 after the company reported VLA2001 met both co-primary endpoints in the Phase 3 pivotal trial Cov-Compare.... 
Via Benzinga
Mid-Morning Market Update: Markets Mostly Lower; Albertsons Tops Q2 Estimates
Following the market opening Monday, the Dow traded down 0.32% to 35,182.99 while the NASDAQ rose 0.12% to 14,915.84. The S&P also fell, dropping 0.06% to 4,468.81. The U.S.... 
Via Benzinga
Topics Stocks
Exposures US Equities
12 Health Care Stocks Moving In Monday's Pre-Market Session
Gainers Valneva (NASDAQ:VALN) stock increased by 35.65% to $38.05 during Monday's pre-market session. The market value of their outstanding shares is at $1.8 billion.... 
Via Benzinga
Omeros Receives Complete Response Letter from FDA for Biologics License Application for Narsoplimab in the Treatment of HSCT-TMA
From Omeros Corporation
Via Business Wire
The Daily Biotech Pulse: NRx Stitches COVID-19 Drug Partnership, Protara Gets Nod For Starting Bladder Cancer Study, IGM Moves Beyond Oncology
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Oct. 11) AstraZeneca Plc (NASDAQ:... 
Via Benzinga
Exposures COVID-19
35 Biggest Movers From Friday
Gainers ChemoCentryx, Inc. (NASDAQ: CCXI) shares surged 96% to close at $38.41 on Friday. The FDA approved ChemoCentryx’s Tavneos (avacopan) as an adjunctive treatment for... 
Via Benzinga
Exposures Product Safety
28 Stocks Moving In Friday's Mid-Day Session
Gainers ChemoCentryx, Inc. (NASDAQ: CCXI) shares climbed 60.8% to $31.51. The FDA approved ChemoCentryx’s Tavneos (avacopan) as an adjunctive treatment for anti-neutrophil... 
Via Benzinga
Exposures Product Safety
Benzinga's Top Ratings Upgrades, Downgrades For October 8, 2021
Upgrades UBS upgraded the previous rating for Northern Trust Corp (NASDAQ: 
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.